A sequential targeting strategy interrupts AKT-driven subclone-mediated progression in glioblastoma
Therapy resistance and fatal disease progression in glioblastoma are thought to result from the dynamics of intra-tumor heterogeneity. This study aimed at identifying and molecularly targeting tumor cells that can survive, adapt, and subclonally expand under primary therapy.To identify candidate mar...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
15 January 2023
|
| In: |
Clinical cancer research
Year: 2023, Volume: 29, Issue: 2, Pages: 488-500 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-22-0611 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-22-0611 Verlag, lizenzpflichtig, Volltext: https://aacrjournals.org/clincancerres/article/29/2/488/713980/A-Sequential-Targeting-Strategy-Interrupts-AKT 
|
| Author Notes: | Sied Kebir, Vivien Ullrich, Pia Berger, Celia Dobersalske, Sarah Langer, Laurèl Rauschenbach, Daniel Trageser, Andreas Till, Franziska K. Lorbeer, Anja Wieland, Timo Wilhelm-Buchstab, Ashar Ahmad, Holger Fröhlich, Igor Cima, Shruthi Prasad, Johann Matschke, Verena Jendrossek, Marc Remke, Barbara M. Grüner, Alexander Roesch, Jens T. Siveke, Christel Herold-Mende, Tobias Blau, Kathy Keyvani, Frank K.H. van Landeghem, Torsten Pietsch, Jörg Felsberg, Guido Reifenberger, Michael Weller, Ulrich Sure, Oliver Brüstle, Matthias Simon, Martin Glas, and Björn Scheffler |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1840224940 | ||
| 003 | DE-627 | ||
| 005 | 20231128085216.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230328s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-22-0611 |2 doi | |
| 035 | |a (DE-627)1840224940 | ||
| 035 | |a (DE-599)KXP1840224940 | ||
| 035 | |a (OCoLC)1389531153 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kebir, Sied |e VerfasserIn |0 (DE-588)1035782421 |0 (DE-627)749559985 |0 (DE-576)383535506 |4 aut | |
| 245 | 1 | 2 | |a A sequential targeting strategy interrupts AKT-driven subclone-mediated progression in glioblastoma |c Sied Kebir, Vivien Ullrich, Pia Berger, Celia Dobersalske, Sarah Langer, Laurèl Rauschenbach, Daniel Trageser, Andreas Till, Franziska K. Lorbeer, Anja Wieland, Timo Wilhelm-Buchstab, Ashar Ahmad, Holger Fröhlich, Igor Cima, Shruthi Prasad, Johann Matschke, Verena Jendrossek, Marc Remke, Barbara M. Grüner, Alexander Roesch, Jens T. Siveke, Christel Herold-Mende, Tobias Blau, Kathy Keyvani, Frank K.H. van Landeghem, Torsten Pietsch, Jörg Felsberg, Guido Reifenberger, Michael Weller, Ulrich Sure, Oliver Brüstle, Matthias Simon, Martin Glas, and Björn Scheffler |
| 264 | 1 | |c 15 January 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht am 14. Oktober 2022 | ||
| 500 | |a Gesehen am 28.11.2023 | ||
| 520 | |a Therapy resistance and fatal disease progression in glioblastoma are thought to result from the dynamics of intra-tumor heterogeneity. This study aimed at identifying and molecularly targeting tumor cells that can survive, adapt, and subclonally expand under primary therapy.To identify candidate markers and to experimentally access dynamics of subclonal progression in glioblastoma, we established a discovery cohort of paired vital cell samples obtained before and after primary therapy. | ||
| 700 | 1 | |a Herold-Mende, Christel |e VerfasserIn |0 (DE-588)1022936549 |0 (DE-627)717335577 |0 (DE-576)366194267 |4 aut | |
| 700 | 1 | |a Scheffler, Björn |d 1971- |e VerfasserIn |0 (DE-588)121203271 |0 (DE-627)705304000 |0 (DE-576)29258444X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 29(2023), 2 vom: Jan., Seite 488-500 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a A sequential targeting strategy interrupts AKT-driven subclone-mediated progression in glioblastoma |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:2 |g month:01 |g pages:488-500 |g extent:13 |a A sequential targeting strategy interrupts AKT-driven subclone-mediated progression in glioblastoma |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-22-0611 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://aacrjournals.org/clincancerres/article/29/2/488/713980/A-Sequential-Targeting-Strategy-Interrupts-AKT |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230328 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1022936549 |a Herold-Mende, Christel |m 1022936549:Herold-Mende, Christel |d 910000 |d 911200 |e 910000PH1022936549 |e 911200PH1022936549 |k 0/910000/ |k 1/910000/911200/ |p 11 | ||
| 999 | |a KXP-PPN1840224940 |e 4298461904 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"title":[{"title":"Clinical cancer research","title_sort":"Clinical cancer research"}],"corporate":[{"role":"isb","display":"American Association for Cancer Research"}],"origin":[{"publisher":"AACR","dateIssuedDisp":"1995-","publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedKey":"1995"}],"disp":"A sequential targeting strategy interrupts AKT-driven subclone-mediated progression in glioblastomaClinical cancer research","id":{"eki":["325489971"],"zdb":["2036787-9"],"issn":["1557-3265"]},"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"pubHistory":["1.1995 -"],"part":{"extent":"13","issue":"2","pages":"488-500","year":"2023","volume":"29","text":"29(2023), 2 vom: Jan., Seite 488-500"},"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["American Association for Cancer Research"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"325489971","language":["eng"]}],"title":[{"title":"A sequential targeting strategy interrupts AKT-driven subclone-mediated progression in glioblastoma","title_sort":"sequential targeting strategy interrupts AKT-driven subclone-mediated progression in glioblastoma"}],"physDesc":[{"noteIll":"Illustrationen","extent":"13 S."}],"language":["eng"],"note":["Online veröffentlicht am 14. Oktober 2022","Gesehen am 28.11.2023"],"person":[{"family":"Kebir","role":"aut","display":"Kebir, Sied","given":"Sied"},{"given":"Christel","display":"Herold-Mende, Christel","role":"aut","family":"Herold-Mende"},{"given":"Björn","display":"Scheffler, Björn","family":"Scheffler","role":"aut"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1840224940","id":{"doi":["10.1158/1078-0432.CCR-22-0611"],"eki":["1840224940"]},"origin":[{"dateIssuedDisp":"15 January 2023","dateIssuedKey":"2023"}],"name":{"displayForm":["Sied Kebir, Vivien Ullrich, Pia Berger, Celia Dobersalske, Sarah Langer, Laurèl Rauschenbach, Daniel Trageser, Andreas Till, Franziska K. Lorbeer, Anja Wieland, Timo Wilhelm-Buchstab, Ashar Ahmad, Holger Fröhlich, Igor Cima, Shruthi Prasad, Johann Matschke, Verena Jendrossek, Marc Remke, Barbara M. Grüner, Alexander Roesch, Jens T. Siveke, Christel Herold-Mende, Tobias Blau, Kathy Keyvani, Frank K.H. van Landeghem, Torsten Pietsch, Jörg Felsberg, Guido Reifenberger, Michael Weller, Ulrich Sure, Oliver Brüstle, Matthias Simon, Martin Glas, and Björn Scheffler"]}} | ||
| SRT | |a KEBIRSIEDHSEQUENTIAL1520 | ||